- Home
- URG vs ANNX Comparison
URG vs ANNX Comparison
Compare URG & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URG
- ANNX
- Stock Information
- Founded
- URG 2004
- ANNX 2011
- Country
- URG United States
- ANNX United States
- Employees
- URG N/A
- ANNX N/A
- Industry
- URG Precious Metals
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- URG Basic Materials
- ANNX Health Care
- Exchange
- URG Nasdaq
- ANNX Nasdaq
- Market Cap
- URG 326.6M
- ANNX 362.4M
- IPO Year
- URG N/A
- ANNX 2020
- Fundamental
- Price
- URG $0.71
- ANNX $1.46
- Analyst Decision
- URG Strong Buy
- ANNX Strong Buy
- Analyst Count
- URG 2
- ANNX 5
- Target Price
- URG $2.45
- ANNX $18.67
- AVG Volume (30 Days)
- URG 5.8M
- ANNX 2.2M
- Earning Date
- URG 04-11-2025
- ANNX 05-12-2025
- Dividend Yield
- URG N/A
- ANNX N/A
- EPS Growth
- URG N/A
- ANNX N/A
- EPS
- URG N/A
- ANNX N/A
- Revenue
- URG $33,706,000.00
- ANNX N/A
- Revenue This Year
- URG $33.74
- ANNX N/A
- Revenue Next Year
- URG $107.58
- ANNX N/A
- P/E Ratio
- URG N/A
- ANNX N/A
- Revenue Growth
- URG 90.66
- ANNX N/A
- 52 Week Low
- URG $0.55
- ANNX $1.29
- 52 Week High
- URG $1.90
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- URG 49.16
- ANNX 30.77
- Support Level
- URG $0.60
- ANNX $1.40
- Resistance Level
- URG $0.73
- ANNX $1.68
- Average True Range (ATR)
- URG 0.07
- ANNX 0.18
- MACD
- URG 0.01
- ANNX 0.00
- Stochastic Oscillator
- URG 88.89
- ANNX 19.13
About URG Ur Energy Inc (Canada)
Ur-Energy Inc is y is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.